Form 4 for CGEM Cullinan Therapeutics, Inc.
Accepted 2024-01-24 00:00:00 ET · period of report 2024-01-22 · accession 0000950170-24-007032 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-01-24 | 2024-01-22+ | CGEM | Savill Corrine | Chief Business Off | M - OptEx | $4.30 | +35.9K | 187.3K | +24% | +$154.3K |
| DMT | 2024-01-24 | 2024-01-22+ | CGEM | Savill Corrine | Chief Business Off | S - Sale+OE | $12.31 | -40.0K | 166.0K | -19% | -$492.5K |
| DMT | 2024-01-24 | 2024-01-22+ | CGEM | Savill Corrine | Chief Business Off | M - OptEx | $0.00 | -35.9K | 14.0K | -72% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-22 | M | A | 14,559 | $4.30 | 184,674 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-22 | S | D | 14,559 | $12.18 | 170,115 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.44. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2024-01-23 | M | A | 21,316 | $4.30 | 187,306 | D | — | — | |
| 4 | Common | Common Stock | 2024-01-22 | S | D | 4,125 | $12.02 | 165,990 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2024-01-23 | S | D | 21,316 | $12.46 | 165,990 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.16 to $12.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Derivative | Stock Option (Right to Buy) | 2024-01-22 | M | D | 14,559 | $0.00 | 35,313 | D | $4.30 · — to 2030-10-28 | 14,559 Common Stock | (F5) 25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023. |
| 7 | Derivative | Stock Option (Right to Buy) | 2024-01-23 | M | D | 21,316 | $0.00 | 13,997 | D | $4.30 · — to 2030-10-28 | 21,316 Common Stock | (F5) 25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023. |